Literature DB >> 32493826

Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals.

Allen Zheng1, Weina Sun1, Xiaoli Xiong2, Alec W Freyn1, Julia Peukes2, Shirin Strohmeier1, Raffael Nachbagauer1, John A G Briggs2, Florian Krammer1, Peter Palese3,4.   

Abstract

Humoral immune protection against influenza virus infection is mediated largely by antibodies against hemagglutinin (HA) and neuraminidase (NA), the two major glycoproteins on the virus surface. While influenza virus vaccination efforts have focused mainly on HA, NA-based immunity has been shown to reduce disease severity and provide heterologous protection. Current seasonal vaccines do not elicit strong anti-NA responses-in part due to the immunodominance of the HA protein. Here, we demonstrate that by swapping the 5' and 3' terminal packaging signals of the HA and NA genomic segments, which contain the RNA promoters, we are able to rescue influenza viruses that express more NA and less HA. Vaccination with formalin-inactivated "rewired" viruses significantly enhances the anti-NA antibody response compared to vaccination with unmodified viruses. Passive transfer of sera from mice immunized with rewired virus vaccines shows better protection against influenza virus challenge. Our results provide evidence that the immunodominance of HA stems in part from its abundance on the viral surface, and that rewiring viral packaging signals-thereby increasing the NA content on viral particles-is a viable strategy for improving the immunogenicity of NA in an influenza virus vaccine.IMPORTANCE Influenza virus infections are a major source of morbidity and mortality worldwide. Increasing evidence highlights neuraminidase as a potential vaccination target. This report demonstrates the efficacy of rewiring influenza virus packaging signals for creating vaccines with more neuraminidase content which provide better neuraminidase (NA)-based protection.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  immunodominance; influenza; neuraminidase; packaging signal; vaccine

Mesh:

Substances:

Year:  2020        PMID: 32493826      PMCID: PMC7394900          DOI: 10.1128/JVI.00742-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

Review 1.  Genome packaging in influenza A virus.

Authors:  Edward C Hutchinson; Johann C von Kirchbach; Julia R Gog; Paul Digard
Journal:  J Gen Virol       Date:  2009-12-02       Impact factor: 3.891

2.  Influenza virus pleiomorphy characterized by cryoelectron tomography.

Authors:  Audray Harris; Giovanni Cardone; Dennis C Winkler; J Bernard Heymann; Matthew Brecher; Judith M White; Alasdair C Steven
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-04       Impact factor: 11.205

3.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

4.  Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.

Authors:  Taia T Wang; Gene S Tan; Rong Hai; Natalie Pica; Erin Petersen; Thomas M Moran; Peter Palese
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

5.  Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans.

Authors:  E D Kilbourne
Journal:  J Infect Dis       Date:  1976-10       Impact factor: 5.226

6.  Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.

Authors:  Felix Broecker; Sean T H Liu; Weina Sun; Florian Krammer; Viviana Simon; Peter Palese
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

Review 7.  Influenza neuraminidase.

Authors:  Gillian M Air
Journal:  Influenza Other Respir Viruses       Date:  2011-11-16       Impact factor: 4.380

8.  Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

Authors:  Matthew R Sandbulte; Gretchen S Jimenez; Adrianus C M Boon; Larry R Smith; John J Treanor; Richard J Webby
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

9.  Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin.

Authors:  Madhusudan Rajendran; Raffael Nachbagauer; Megan E Ermler; Paul Bunduc; Fatima Amanat; Ruvim Izikson; Manon Cox; Peter Palese; Maryna Eichelberger; Florian Krammer
Journal:  mBio       Date:  2017-03-21       Impact factor: 7.867

10.  Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.

Authors:  Matthew J Memoli; Pamela A Shaw; Alison Han; Lindsay Czajkowski; Susan Reed; Rani Athota; Tyler Bristol; Sarah Fargis; Kyle Risos; John H Powers; Richard T Davey; Jeffery K Taubenberger
Journal:  mBio       Date:  2016-04-19       Impact factor: 7.867

View more
  8 in total

1.  The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.

Authors:  Atsushi Kawai; Yasuyuki Yamamoto; Takuto Nogimori; Kohei Takeshita; Takuya Yamamoto; Yasuo Yoshioka
Journal:  J Virol       Date:  2021-08-11       Impact factor: 5.103

2.  Differential Recognition of Computationally Optimized H3 Hemagglutinin Influenza Vaccine Candidates by Human Antibodies.

Authors:  Nada Abbadi; Kaito Nagashima; Alma Pena-Briseno; Ted M Ross; Jarrod J Mousa
Journal:  J Virol       Date:  2022-08-02       Impact factor: 6.549

3.  An influenza virus vector candidate vaccine stably expressing SARS-CoV-2 receptor-binding domain produces high and long-lasting neutralizing antibodies in mice.

Authors:  Yongzhen Zhao; Lingcai Zhao; Yingfei Li; Qingzheng Liu; Lulu Deng; Yuanlu Lu; Xiaoting Zhang; Shengmin Li; Jinying Ge; Zhigao Bu; Jihui Ping
Journal:  Vet Microbiol       Date:  2022-06-09       Impact factor: 3.246

4.  Interactions between Influenza A Virus Nucleoprotein and Gene Segment Untranslated Regions Facilitate Selective Modulation of Viral Gene Expression.

Authors:  Meghan Diefenbacher; Timothy J C Tan; David L V Bauer; Beth M Stadtmueller; Nicholas C Wu; Christopher B Brooke
Journal:  J Virol       Date:  2022-04-25       Impact factor: 6.549

Review 5.  Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response.

Authors:  Mark B Carascal; Rance Derrick N Pavon; Windell L Rivera
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

6.  Influenza A viruses balance ER stress with host protein synthesis shutoff.

Authors:  Beryl Mazel-Sanchez; Justyna Iwaszkiewicz; Joao P P Bonifacio; Filo Silva; Chengyue Niu; Shirin Strohmeier; Davide Eletto; Florian Krammer; Gene Tan; Vincent Zoete; Benjamin G Hale; Mirco Schmolke
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-07       Impact factor: 11.205

Review 7.  Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.

Authors:  Sarah Creytens; Mirte N Pascha; Marlies Ballegeer; Xavier Saelens; Cornelis A M de Haan
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

8.  Structure-based design of stabilized recombinant influenza neuraminidase tetramers.

Authors:  Daniel Ellis; Julia Lederhofer; Oliver J Acton; Yaroslav Tsybovsky; Sally Kephart; Christina Yap; Rebecca A Gillespie; Adrian Creanga; Audrey Olshefsky; Tyler Stephens; Deleah Pettie; Michael Murphy; Claire Sydeman; Maggie Ahlrichs; Sidney Chan; Andrew J Borst; Young-Jun Park; Kelly K Lee; Barney S Graham; David Veesler; Neil P King; Masaru Kanekiyo
Journal:  Nat Commun       Date:  2022-04-05       Impact factor: 17.694

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.